Credit Suisse’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $140K | Sell |
58,431
-262,070
| -82% | -$645K | ﹤0.01% | 2919 |
|
|
2023
Q4 | $1.07M | Sell |
320,501
-44,005
| -12% | -$118K | ﹤0.01% | 2295 |
|
|
2023
Q3 | $1.36M | Sell |
364,506
-17,851
| -5% | -$82.5K | ﹤0.01% | 2078 |
|
|
2023
Q2 | $1.63M | Sell |
382,357
-27,911
| -7% | -$165K | ﹤0.01% | 2068 |
|
|
2023
Q1 | $2.81M | Sell |
410,268
-28,256
| -6% | -$219K | ﹤0.01% | 1672 |
|
|
2022
Q4 | $3.47M | Sell |
438,524
-35,087
| -7% | -$270K | ﹤0.01% | 1546 |
|
|
2022
Q3 | $4.55M | Buy |
473,611
+220,374
| +87% | +$2.23M | 0.01% | 1311 |
|
|
2022
Q2 | $1.83M | Buy |
253,237
+40,563
| +19% | +$353K | ﹤0.01% | 1981 |
|
|
2022
Q1 | $2.74M | Buy |
212,674
+8,740
| +4% | +$111K | ﹤0.01% | 1863 |
|
|
2021
Q4 | $3.25M | Sell |
203,934
-158,580
| -44% | -$2.77M | ﹤0.01% | 2386 |
|
|
2021
Q3 | $5.83M | Buy |
362,514
+168,621
| +87% | +$2.47M | ﹤0.01% | 1936 |
|
|
2021
Q2 | $2.68M | Sell |
193,893
-46,909
| -19% | -$664K | ﹤0.01% | 2618 |
|
|
2021
Q1 | $3.52M | Sell |
240,802
-23,168
| -9% | -$393K | ﹤0.01% | 2367 |
|
|
2020
Q4 | $4.59M | Buy |
263,970
+11,130
| +4% | +$198K | ﹤0.01% | 2165 |
|
|
2020
Q3 | $4.64M | Sell |
252,840
-55,828
| -18% | -$1.04M | ﹤0.01% | 1842 |
|
|
2020
Q2 | $5.51M | Buy |
308,668
+133,939
| +77% | +$2.27M | ﹤0.01% | 1650 |
|
|
2020
Q1 | $2.83M | Sell |
174,729
-108,438
| -38% | -$2M | ﹤0.01% | 1895 |
|
|
2019
Q4 | $5.1M | Sell |
283,167
-101,690
| -26% | -$1.88M | ﹤0.01% | 1863 |
|
|
2019
Q3 | $7.8M | Buy |
384,857
+246,898
| +179% | +$4.93M | 0.01% | 1458 |
|
|
2019
Q2 | $3.05M | Sell |
137,959
-44,795
| -25% | -$778K | ﹤0.01% | 2139 |
|
|
2019
Q1 | $2.49M | Sell |
182,754
-5,376
| -3% | -$71.7K | ﹤0.01% | 2214 |
|
|
2018
Q4 | $1.7M | Sell |
188,130
-1,562
| -0.8% | -$18.1K | ﹤0.01% | 2358 |
|
|
2018
Q3 | $3.13M | Sell |
189,692
-29,559
| -13% | -$524K | ﹤0.01% | 2011 |
|
|
2018
Q2 | $3.07M | Buy |
219,251
+71,691
| +49% | +$1.03M | ﹤0.01% | 2109 |
|
|
2018
Q1 | $1.63M | Buy |
147,560
+35,856
| +32% | +$392K | ﹤0.01% | 2584 |
|
|
2017
Q4 | $982K | Sell |
111,704
-30,778
| -22% | -$329K | ﹤0.01% | 3006 |
|
|
2017
Q3 | $1.9M | Sell |
142,482
-7,270
| -5% | -$96.2K | ﹤0.01% | 2585 |
|
|
2017
Q2 | $2.15M | Sell |
149,752
-14,361
| -9% | -$276K | ﹤0.01% | 2182 |
|
|
2017
Q1 | $3.47M | Buy |
164,113
+21,958
| +15% | +$540K | ﹤0.01% | 1914 |
|
|
2016
Q4 | $4M | Sell |
142,155
-30,084
| -17% | -$842K | ﹤0.01% | 1821 |
|
|
2016
Q3 | $4.61M | Buy |
172,239
+133,249
| +342% | +$3.63M | ﹤0.01% | 1726 |
|
|
2016
Q2 | $659K | Buy |
38,990
+11,090
| +40% | +$208K | ﹤0.01% | 3254 |
|
|
2016
Q1 | $592K | Sell |
27,900
-6,029
| -18% | -$98.8K | ﹤0.01% | 3126 |
|
|
2015
Q4 | $780K | Buy |
+33,929
| New | +$873K | ﹤0.01% | 3029 |
|
|
2015
Q3 | – | Sell |
-9,821
| Closed | -$284K | – | 4284 |
|
|
2015
Q2 | $284K | Buy |
+9,821
| New | +$248K | ﹤0.01% | 4041 |
|
Other funds holding CHRS
RCMNY
KKRC
Credit Suisse's CHRS Position: Q1 2024 in Review
Credit Suisse reduced its Coherus Oncology (CHRS) stake by 82% in Q1 2024, selling an estimated $645K and leaving 58,431 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2919.
Credit Suisse first reported a position in CHRS in Q2 2015 and has held it in 35 quarters since. The position peaked at $7.8M in Q3 2019. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.
- Credit Suisse held 58,431 shares of Coherus Oncology worth $140K as of Q1 2024.
- Credit Suisse sold 262,070 Coherus Oncology shares in Q1 2024, an estimated $645K.
- Coherus Oncology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2919 holding.
- Credit Suisse first reported a position in Coherus Oncology in Q2 2015 and has held it in 35 quarters since.
- Credit Suisse's Coherus Oncology position peaked at $7.8M in Q3 2019.
- 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.